EUVIMEDEUVIMED entdecken
Crossref

Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine

Catarina Pinto, Romana Bischl, Lea Knezevic, Sarah Ahmadi-Erber, Katell Bidet Huang, Sarah Schmidt, Peter Steinberger, Klaus K Orlinger, Henning Lauterbach, Josipa Raguz

Cancer Gene Therapy · 2026

DOI: 10.1038/s41417-026-01034-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Gene Therapy, 2026. Verfasst von Catarina Pinto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hookipa Pharma Inc., New York, NY, USA. Hauptthemen laut MEDLINE: Cancer Vaccines, Proto-Oncogene Proteins p21(ras), Mutation, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS mutations are frequent oncogenic drivers in several indications, yet limited targeted therapy options are available. Here we engineered our clinically validated artARENA platform to develop an "off-the-shelf" shared neoantigen vaccine, capable of triggering potent CD8+ T-cell responses against the five most prevalent KRAS mutations (G12D, G12V, G12C, G12R, and G13D). Alternating two-vector therapy (sequential administration of artPICV-based vector followed by artLCMV-based vector, encoding the same optimized antigen construct) induced KRAS neoepitope-specific polyfunctional T-cell responses in HLA transgenic mouse strains, showing direct cytotoxicity against KRAS-mutant cell targets in an in vivo assay. Importantly, no cross-reactivity to wt KRAS was observed, highlighting the safety of the approach. Immunogenicity data in mice was corroborated in vitro using T cell stimulation assays, confirming the antigenicity of the construct. Taken together, these results and the clinically validated favorable safety and immunogenicity profiles of our platform warrant clinical translation of this program with the aim to provide more durable and comprehensive tumor control in patients harboring KRAS mutated tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesProto-Oncogene Proteins p21(ras)MutationNeoplasmsAnimalsMiceHumansMice, TransgenicCD8-Positive T-Lymphocytes

Substanzen

Cancer VaccinesProto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Hookipa Pharma Inc., New York, NY, USA.
  • Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
  • Hookipa Pharma Inc., New York, NY, USA. josipa.raguz@hookipapharma.com.

Zitieren

APA

Pinto, C., Bischl, R., Knezevic, L., Ahmadi-Erber, S., Bidet Huang, K., Schmidt, S., Steinberger, P., Orlinger, K. K., Lauterbach, H., & Raguz, J. (2026). Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine. Cancer Gene Therapy. https://doi.org/10.1038/s41417-026-01034-7

Vancouver

Pinto C, Bischl R, Knezevic L, Ahmadi-Erber S, Bidet Huang K, Schmidt S, et al. Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine. Cancer Gene Therapy. 2026. doi:10.1038/s41417-026-01034-7

BibTeX
@article{Pinto2026,
  author = {Pinto, Catarina and Bischl, Romana and Knezevic, Lea and Ahmadi-Erber, Sarah and Bidet Huang, Katell and Schmidt, Sarah and Steinberger, Peter and Orlinger, Klaus K and Lauterbach, Henning and Raguz, Josipa},
  title = {Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine},
  journal = {Cancer Gene Therapy},
  year = {2026},
  doi = {10.1038/s41417-026-01034-7}
}
Kostenlos starten →